The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Petrov I.A.

Department of Obstetrics and Gynecology, Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia

Dmitrieva M.L.

Department of Obstetrics and Gynecology, Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia

Tikhonovskaya O.A.

Department of Obstetrics and Gynecology, Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia

Petrova M.S.

Department of Obstetrics and Gynecology, Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia

Logvinov S.V.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk

Dehydroepiandrosterone in the ovarian insufficiency (a review)

Authors:

Petrov I.A., Dmitrieva M.L., Tikhonovskaya O.A., Petrova M.S., Logvinov S.V.

More about the authors

Journal: Russian Journal of Human Reproduction. 2016;22(6): 24‑32

DOI: 10.17116/repro201622624-32

Read: 51313 times

Download PDF (RU)
Contact the author
Table of contents

DEHYDROEPIANDROSTERONE IN THE OVARIAN INSUFFICIENCY (A REVIEW)
DEHYDROEPIANDROSTERONE IN THE OVARIAN INSUFFICIENCY (A REVIEW)

To cite this article:

Petrov IA, Dmitrieva ML, Tikhonovskaya OA, Petrova MS, Logvinov SV. Dehydroepiandrosterone in the ovarian insufficiency (a review). Russian Journal of Human Reproduction. 2016;22(6):24‑32. (In Russ.)
https://doi.org/10.17116/repro201622624-32

 
Подписка 2026 Проблемы репродукции (Russian Journal of Human Reproduction)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Features of the course of indu­ced pregnancy during the transfer of a thawed embryo in women with poly­cystic ovary syndrome. Russian Journal of Human Reproduction. 2025;(1):54-62
Nutrient status of follicular fluid and blood serum in women with infe­rtility as a marker of embryo quality. Pilot study. Russian Journal of Human Reproduction. 2025;(2):17-27
To the question of human oocy­tes dysmorphism and its influence on the para­meters of early embryogenesis. Russian Journal of Human Reproduction. 2025;(3):48-54
Prediction of pregnancy in ART cycles in Hashimoto’s thyroiditis affe­cted women with anti­thyroid anti­bodies posi­tivity. Russian Journal of Human Reproduction. 2025;(3):70-76
Comparative analysis of oocyte quality in patients with tubal-peritoneal gene­sis of infe­rtility in assi­sted reproductive technology programs. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):41-49
The expe­rience of using the nasal form of GnRH agonists in in vitro fertilization programs. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):79-84
Awareness of women about the prevention and correction of climacteric diso­rders. Russian Journal of Preventive Medi­cine. 2025;(1):57-62
The possibilities of predicting and redu­cing the risk of breast cancer in women against the background of the use of assi­sted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):59-64
Medi­cal and social characteristics of mate­rnal deaths after extracorporeal fertilization. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):5-14
Primary ovarian insu­fficiency: oppo­rtunities and prospects for the realization of reproductive function. Russian Bulletin of Obstetrician-Gynecologist. 2025;(2):42-47
Abstract:

Dehydroepiandrosterone (DHEA) is a major source of androgens in women. The age decrease of prohormone associated with deficiency of estrogen and androgen. Testosterone is used for various diseases and conditions in women as an off-label treatment in addition to the traditional menopausal hormone replacement therapy or as a monotherapy. DHEA is proposed to use in postmenopausal women considering the essential role of precursors of sex steroids in the female body, decrease of DHEA with age, the negative relationship of prohormone and sexual well-being, the positive effects of steroid hormones on sexual function. Prohormones also used as an adjuvant in protocols in vitro fertilization to improve the response of the gonads and pregnancy rates in women with reduced ovarian reserve. So far, studies of long-term consequences and risks of this practice are absent. Most systematic reviews relatively of DHEA-replacement therapy of age-related conditions does not support its routine use due to inconsistencies the high criteria of evidence-based medicine. We conducted a literature search aimed to investigate the clinical efficacy and safety of DHEA in the treatment of menopausal symptoms and in assisted reproductive technologies.

Keywords:

dehydroepiandrosterone
intracrinology
menopause
assisted reproductive technologies

Authors:

Petrov I.A.

Department of Obstetrics and Gynecology, Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia

Dmitrieva M.L.

Department of Obstetrics and Gynecology, Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia

Tikhonovskaya O.A.

Department of Obstetrics and Gynecology, Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia

Petrova M.S.

Department of Obstetrics and Gynecology, Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia

Logvinov S.V.

Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Tomsk

Close metadata

References:

  1. Shampo M, Kyle R, Steensma D. Adolf Butenandt—Nobel Prize for Chemistry. Mayo Clinic Proceedings. 2012;87(4):e27. doi: 10.1016/j.mayocp.2011.12.019
  2. Goncharov N, Katsiya G. Dehydroepiandrosterone biosynthesis, metabolism, biological effects, and clinical use (analytical review). Androl Genit Hir. 2015;16(1):13. (In Russ.). doi: 10.17650/2070-9781-2015-1-13-22 doi: 10.17650/2070-9781-2015-1-13-22
  3. Shohat-Tal A, Sen A, Barad D, Kushnir V, Gleicher N. Genetics of androgen metabolism in women with infertility and hypoandrogenism. Nat Rev Endocrinol. 2015;11(7):429-441. doi: 10.1038/nrendo.2015.64
  4. Gleicher N, Weghofer A, Barad D. Defining ovarian reserve to better understand ovarian aging. Reprod Biol Endocrinol. 2011;9(1):23. doi: 10.1186/1477-7827-9-23
  5. Sen A, Hammes S. Granulosa Cell-Specific Androgen Receptors Are Critical Regulators of Ovarian Development and Function. The Journal of Clinical Endocrinology & Metabolism. 2010;95(6):3078-3078. doi: 10.1210/jcem.95.6.9996
  6. Gleicher N, Weghofer A, Barad D. The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment? Reprod Biol Endocrinol. 2011;9(1):116. doi: 10.1186/1477-7827-9-116
  7. Miller W, Auchus R. The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders. Endocrine Reviews. 2011;32(1):81-151. doi: 10.1210/er.2010-0013
  8. Samaras N, Papadopoulou M, Samaras D, Ongaro F. Off-label use of hormones as an antiaging strategy: a review. CIA. 2014;1175. doi: 10.2147/cia.s48918
  9. Lois K, Kassi E, Prokopiou M, Chrousos G.P. Adrenal Androgens and Aging. [Updated 2014 Jun 18]. In: De Groot LJ, Chrousos G, Dungan K, et al. (editors). Endotext [электронныйресурс]. South Dartmouth (MA): MDText.com, Inc.; 2000.Доступно по: http://www.ncbi.nlm.nih.gov/books/NBK279006/ Ssylka aktivna na 03.09.2016.
  10. Labrie F. Intracrinology. Molecular and Cellular Endocrinology. 1991;78(3):C113-C118. doi: 10.1016/0303-7207(91)90116-a
  11. Bachmann G. Androgen cotherapy in menopause: Evolving benefits and challenges. American Journal of Obstetrics and Gynecology. 1999;180(3):S308-S311. doi: 10.1016/s0002-9378(99)70724-6
  12. Flöter A, Nathorst-böös J, Carlström K, Ohlsson C, Ringertz H, von Schoultz B. Effects of combined estrogen/testosterone therapy on bone and body composition in oophorectomized women. Gynecological Endocrinology. 2005;20(3):155-160. doi: 10.1080/09513590400021193
  13. Panjari M, Davis S. DHEA for postmenopausal women: a review of the evidence. Maturitas. 2010;66(2):172-179. doi: 10.1016/j.maturitas.2009.12.017
  14. Alkatib A, Cosma M, Elamin M, Erickson D, Swiglo B, Erwin P, Montori V. A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials of DHEA Treatment Effects on Quality of Life in Women with Adrenal Insufficiency. The Journal of Clinical Endocrinology & Metabolism. 2009;94(10):3676-3681. doi: 10.1210/jc.2009-0672
  15. Panjari M, Bell R, Jane F, Wolfe R, Adams J, Morrow C, Davis S. A Randomized Trial of Oral DHEA Treatment for Sexual Function, Well-Being, and Menopausal Symptoms in Postmenopausal Women with Low Libido. The Journal of Sexual Medicine. 2009;6(9):2579-2590. doi: 10.1111/j.1743-6109.2009.01381.x
  16. Elraiyah T, Sonbol M, Wang Z, Khairalseed T, Asi N, Undavalli C, Nabhan M, Altayar O, Prokop L, Montori V, Murad M. The Benefits and Harms of Systemic Dehydroepiandrosterone (DHEA) in Postmenopausal Women With Normal Adrenal Function: A Systematic Review and Metaanalysis. The Journal of Clinical Endocrinology & Metabolism. 2014;99(10):3536-3542. doi: 10.1210/jc.2014-2261
  17. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez J, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009;16(5):923-931. doi: 10.1097/gme.0b013e31819e85c6
  18. Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev. 2015 Jan 22;1:CD011066. doi: 10.1002/14651858.CD011066.pub2
  19. Gupta B, Mittal P, Khuteta R, Bhargava A. A Comparative Study of CEE, Tibolone, and DHEA as Hormone Replacement Therapy for Surgical Menopause. J Obstet Gynecol India. 2012;63(3):194-198. doi: 10.1007/s13224-012-0297-7
  20. Patrizio P, Vaiarelli A, Levi Setti P, Tobler K, Shoham G, Leong M, Shoham Z. How to define, diagnose and treat poor responders? Responses from a worldwide survey of IVF clinics. Reproductive BioMedicine Online. 2015;30(6):581-592. doi: 10.1016/j.rbmo.2015.03.002
  21. Nardo L, El-Toukhy T, Stewart J, Balen A, Potdar N. British Fertility Society Policy and Practice Committee: Adjuvants in IVF: Evidence for good clinical practice. Human Fertility. 2014;18(1):2-15. doi: 10.3109/14647273.2015.985454
  22. Narkwichean A, Maalouf W, Campbell B, Jayaprakasan K. Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis. Reprod Biol Endocrinol. 2013;11(1):44. doi: 10.1186/1477-7827-11-44
  23. Casson P. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Human Reproduction. 2000;15(10):2129-2132. doi: 10.1093/humrep/15.10.2129
  24. Walters K, Simanainen U, Handelsman D. Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models. Human Reproduction Update. 2010;16(5):543-558. doi: 10.1093/humupd/dmq003
  25. Nielsen M, Rasmussen I, Kristensen S, Christensen S, Mollgard K, Wreford, Andersen E, Byskov A, Yding Andersen C. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Molecular Human Reproduction. 2010;17(1):63-70. doi: 10.1093/molehr/gaq073
  26. Ménézo Y, Dale B, Cohen M. DNA damage and repair in human oocytes and embryos: a review. Zygote. 2010;18(04):357-365. doi: 10.1017/s0967199410000286
  27. Pitteloud N, Mootha V, Dwyer A, Hardin M, Lee H, Eriksson K, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes F. Relationship Between Testosterone Levels, Insulin Sensitivity, and Mitochondrial Function in Men. Diabetes Care. 2005;28(7):1636-1642. doi: 10.2337/diacare.28.7.1636
  28. Bosdou J, Venetis C, Kolibianakis E, Toulis K, Goulis D, Zepiridis L, Tarlatzis B. The use of androgens or androgen-modulating agents in poor responders undergoing in vitro fertilization: a systematic review and metaanalysis. Human Reproduction Update. 2012;18(2):127-145. doi: 10.1093/humupd/dmr051
  29. Li J, Yuan H, Chen Y, Wu H, Wu H, Li L. A metaanalysis of dehydroepiandrosterone supplementation among women with diminished ovarian reserve undergoing in vitro fertilization or intracytoplasmic sperm injection. International Journal of Gynecology & Obstetrics. 2015;131(3):240-245. doi: 10.1016/j.ijgo.2015.06.028
  30. Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst Rev. 2015 Nov 26;(11):CD009749. doi: 10.1002/14651858.CD009749.pub2
  31. Zhang M, Niu W, Wang Y, Xu J, Bao X, Wang L, Du L, Sun Y. . Dehydroepiandrosterone treatment in women with poor ovarian response undergoing IVF or ICSI: a systematic review and meta-analysis. Journal of Assisted Reproduction and Genetics. 2016;33(8):981-991. doi: 10.1007/s10815-016-0713-5
  32. Qin J, Fan L, Qin A. The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evidence from a meta-analysis. Journal de Gynécologie Obstétrique et Biologie de la Reproduction. 2016. doi: 10.1016/j.jgyn.2016.01.002
  33. Tartagni M, De Pergola G, Damiani GR, Pellegrino A, Baldini D, Tartagni MV, Alrasheed H, De Salvia MA, Loverro G. Potential benefit of dehydroepiandrosterone supplementation for infertile but not poor responder patients in aIVF program. Minerva Ginecologica. 2015;67(1):7-12.
  34. Yeung T, Chai J, Li R, Lee V, Ho P, Ng E. A double-blind randomised controlled trial on the effect of dehydroepiandrosterone on ovarian reserve markers, ovarian response and number of oocytes in anticipated normal ovarian responders. BJOG: An International Journal of Obstetrics & Gynaecology. 2016;123(7):1097-1105. doi: 10.1111/1471-0528.13808
  35. Kotb M, Hassan A, Awad Allah A. Does dehydroepiandrosterone improve pregnancy rate in women undergoing IVF/ICSI with expected poor ovarian response according to the Bologna criteria? A randomized controlled trial. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2016;200:11-15. doi: 10.1016/j.ejogrb.2016.02.009
  36. Kara M, Aydin T, Aran T, Turktekin N, Ozdemir B. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve?.European Journal of Obstetrics & Gynecology and Reproductive Biology. 2014;173:63-65. doi: 10.1016/j.ejogrb.2013.11.008
  37. Liu X, Wang W, Wang X, Qu Q, Hao C. Effect of dehydroepiandrosterone administration in Chinese women over 37 years undergoing assisted reproductive techniques. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2016;202:9-13. doi: 10.1016/j.ejogrb.2016.04.028
  38. Gat I, Blanco Mejia S, Balakier H, Librach C, Claessens A, Ryan E. The use of coenzyme Q10 and DHEA during IUI and IVF cycles in patients with decreased ovarian reserve. Gynecological Endocrinology. 2016;32(7):534-537. doi: 10.3109/09513590.2015.1137095
  39. Franasiak J, Thomas S, Ng S, Fano M, Ruiz A, Scott R, Forman E. Dehydroepiandrosterone (DHEA) supplementation results in supraphysiologic DHEA-S serum levels and progesterone assay interference that may impact clinical management in IVF. Journal of Assisted Reproduction and Genetics. 2016;33(3):387-391. doi: 10.1007/s10815-016-0650-3
  40. Tsui K, Lin L, Chang R, Huang B, Cheng J, Wang P. Effects of dehydroepiandrosterone supplementation on women with poor ovarian response: A preliminary report and review. Taiwanese Journal of Obstetrics and Gynecology. 2015;54(2): 131-136. doi: 10.1016/j.tjog.2014.07.007
  41. Vlahos N, Papalouka M, Triantafyllidou O, Vlachos A, Vakas P, Grimbizis G, Creatsas G, Zikopoulos K. Dehydroepiandrosterone administration before IVF in poor responders: a prospective cohort study. Reproductive BioMedicine Online. 2015;30(2):191-196. doi: 10.1016/j.rbmo.2014.10.005
  42. Jirge P, Bhomkar D, Chougule S, Gavali V. Impact of dehydroepiandrosterone on clinical outcome in poor responders: A pilot study in women undergoing in vitro fertilization, using bologna criteria. J Hum Reprod Sci. 2014;7(3):175. doi: 10.4103/0974-1208.142477
  43. Zangmo R, Singh N, Kumar S, Vanamail P, Tiwari A. Role of dehydroepiandrosterone in improving oocyte and embryo quality in IVF cycles. Reproductive BioMedicine Online. 2014;28(6):743-747. doi: 10.1016/j.rbmo.2014.01.019
  44. Fusi F, Ferrario M, Bosisio C, Arnoldi M, Zanga L. DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function. Gynecological Endocrinology. 2013;29(10):940-943. doi: 10.3109/09513590.2013.819087
  45. Gleicher N, Kim A, Weghofer A, Shohat-Tal A, Lazzaroni E, Lee H, Barad D. Starting and resulting testosterone levels after androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR). Journal of Assisted Reproduction and Genetics. 2012;30(1):49-62. doi: 10.1007/s10815-012-9890-z
  46. Singh N, Zangmo R, Kumar S, Roy K, Sharma J, Malhotra N, Vanamail P. A prospective study on role of dehydroepiandrosterone (DHEA) on improving the ovarian reserve markers in infertile patients with poor ovarian reserve. Gynecological Endocrinology. 2013;29(11):989-992. doi: 10.3109/09513590.2013.824957
  47. Giovanni Artini P, Simi G, Ruggiero M, Pinelli S, Di Berardino O, Papini F, Papini S, Monteleone P, Cela V. DHEA supplementation improves follicular microenviroment in poor responder patients. Gynecological Endocrinology. 2012;28(9):669-673. doi: 10.3109/09513590.2012.705386
  48. Sunkara S, Pundir J, Khalaf Y. Effect of androgen supplementation or modulation on ovarian stimulation outcome in poor responders: a meta-analysis. Reproductive BioMedicine Online. 2011;22(6):545-555. doi: 10.1016/j.rbmo.2011.01.015
  49. Fertility: assessment and treatment for people with fertility problems (NICE clinical guideline 156) [электронныйресурс]. Manchester: National Institute for Health and Clinical Excellence, 2013 Feb. Доступно по: http://www.nice.org.uk/guidance/cg156. Ссылка активна на 03.09.2016
  50. Gleicher N. Randomised controlled trials on dehydroepiandrosterone supplementation in female infertility still not conclusive. BJOG: An International Journal of Obstetrics & Gynaecology. 2016;123(7):1106-1106. doi: 10.1111/1471-0528.13945
  51. Mamas L, Mamas E. Premature ovarian failure and dehydroepiandrosterone. Fertility and Sterility. 2009;91(2):644-646. doi: 10.1016/j.fertnstert.2007.11.055
  52. Barad D, Weghofer A, Gleicher N. Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function. Fertility and Sterility. 2009;91(4):1553-1555. doi: 10.1016/j.fertnstert.2008.09.069
  53. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Human Reproduction. 2006;21(11):2845-2849. doi: 10.1093/humrep/del254
  54. Gleicher N, Weghofer A, Barad D. Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS). Reprod Biol Endocrinol. 2010;8(1):140. doi: 10.1186/1477-7827-8-140
  55. Naredi N, Sandeep K, Jamwal V, Nagraj N, Rai S. Dehydroepiandrosterone: A panacea for the ageing ovary?.Medical Journal Armed Forces India. 2015;71(3):274-277. doi: 10.1016/j.mjafi.2014.12.022
  56. Gleicher N, Barad D. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol. 2011;9(1):67. doi: 10.1186/1477-7827-9-67
  57. Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): Hypes and Hopes. Drugs. 2014;74(11): 1195-1207. doi: 10.1007/s40265-014-0259-8
  58. Lang P, Mitchell W, Lapenna A, Pitts D, Aspinall R. Immunological pathogenesis of main age-related diseases and frailty: Role of immunosenescence. European Geriatric Medicine. 2010;1(2):112-121. doi: 10.1016/j.eurger.2010.01.010
  59. Marwah A, Marwah P, Lardy H. Ergosteroids. VI. Metabolism of dehydroepiandrosterone by rat liver in vitro: a liquid chromatographic-mass spectrometric study. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Feb 15;767(2):285-299.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.